Skip to content

Vascular Closure

Rapid hemostasis for arterial and venous access sites
Our portfolio of vascular closure products provides rapid hemostasis for interventional and electrophysiology procedures to help clinicians reduce the risk of complications, improve patient satisfaction, and enable same day discharge.

Haemonetics Vascular Closure VASCADE
Optimizing Vascular Access Management
• Enables same day discharge following AF ablation with VASCADE MVP® Venous Vascular Closure System (VVCS)
• Reduces the risk of access site complications with VASCADE® Vascular Closure System (VCS), as demonstrated in the RESPECT Clinical Trial1
• Offers an outcomes-based risk-sharing VASCADE Performance Guarantee program – Sharing Risk by Sharing Costs
1. Hermiller JB, A Prospective, Randomized, Pivotal Trial of a Novel Extravascular Collagen-Based Closure Device Compared to Manual Compression in Diagnostic and Interventional Patients Journal of Invasive Cardiology 2015;27(3):129-136.

2. IFUs and / or SSEDs of commercially available leading brands (VASCADE®, AngioSeal®, Mynx®, Perclose™, Starclose™, Exoseal®).

3. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.

4. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system. VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.

5. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.

6/7. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. J Cardiovasc Electrophysiol 2022. NCT04203329.


Connect with Vascular Closure

Haemonetics Vascular Closure LinkedIn    Haemonetics Vascular Closure Twitter